Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke ( ischaemic stroke significantly improve...)

HOME >> MEDICINE >> TECHNOLOGY

Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke

ischaemic stroke, significantly improves clinical outcome at three months. Alteplase is an enzyme that occurs naturally in humans and causes blood clots to dissolve.

*) Actilyse® (alteplase) is registered in 85 countries across the world and marketed outside North America and Japan by Boehringer Ingelheim.

About SITS-MOST (Safe Implementation of Thrombolysis in Stroke - MOnitoring STudy)
Systematic reviews of randomised controlled trials indicate that treatment with thrombolytics is highly beneficial when given within three hours from onset of stroke symptoms. SITS-MOST, the world’s largest stroke registry/network for acute stroke centres, has demonstrated that broad implementation of thrombolysis in acute stroke treatment is both as safe and as effective in routine clinical practice as it has been shown to be in randomised clinical trials. Data from SITS-MOST (n=6483) show that ‘real-life’ treatment with Actilyse® within three hours resulted in both improved mortality (11.3% vs. 17.3%) and safety (symptomatic intracerebral haemorrhage 7.3% vs. 8.6%) when compared to randomised controlled trials.2

SITS-MOST is embedded within the Safe Implementation of Thrombolysis in Stroke International Stroke Thrombolysis Register (SITS-ISTR), an internet-based, international monitoring registry for auditing the safety and efficacy of routine therapeutic use of thrombolysis in acute ischaemic stroke. The registry is available to clinicians in many countries worldwide except Japan and North America. Acute stroke treatment with thrombolysis is currently under-used with wide variations from country to country and region to region. Less than two percent of overall stroke patients in the EU currently receive thrombolysis.

About ECASS III
The objective of the ECASS III study is to evaluate the efficacy and safety of intravenous thrombolysis using Actilyse® in patients with acute ischaemic stroke and confirm that the
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
2. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
3. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
4. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
5. First-of-its-Kind National Report Reveals Estimated High Prevalence and Heavy Cost of Type 2 Diabetes Complications in America
6. Research Results on FluMist Presented at National Association of Pediatric Nurse Practitioners Conference
7. Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
8. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
9. Advanced Magnetics Announces Presentation of Ferumoxytol Data at the National Kidney Foundation 2007 Spring Clinical Meetings
10. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
11. Southern Research Institute to Present at the 2007 American Association For Cancer Research Annual Meeting

Post Your Comments:

(Date:12/16/2009)... A new application developed by American ... of specialty pharmaceuticals has increased health plan staff ... reducing costs. ,, AIM, a leading diagnostic imaging ... clients representing over 35 million consumers and an ... WLP ), adapted the successful clinical and technology ...

(Date:12/16/2009)... Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or the ... bridge loan financing (the "2009 Financing") pursuant to ... "Agreement") with Firebird Global Master Fund, Ltd., ("Firebird"). ... convertible promissory note, due June 30, 2010, in ... a warrant to purchase an aggregate of 93,333,333 ...

(Date:12/16/2009)... Dec. 16 Boston Scientific Corporation (NYSE: ... of Directors has elected Nelda Connors as a Director. ... the Electrical and Metal Products division of Tyco International. ... Corporation, holding several positions in operations and general management. ... a number of executive and management capacities with Ford, ...

Breaking Medicine Technology:American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4 AVAX Technologies, Inc. Closes Bridge Financing 2 AVAX Technologies, Inc. Closes Bridge Financing 3 AVAX Technologies, Inc. Closes Bridge Financing 4 Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 2 Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 3 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 1 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 2 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 3 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 4 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 5 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 6 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 7 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 8 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 9 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 10 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 11 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 12 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 13 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 14 Professor Steven Ley of University of Cambridge will Present Free Webinar 26apos 3BApplication of the ReactIR Flow Cell to Continuous Processing Tec 14728 1 Professor Steven Ley of University of Cambridge will Present Free Webinar 26apos 3BApplication of the ReactIR Flow Cell to Continuous Processing Tec 14728 2 Professor Steven Ley of University of Cambridge will Present Free Webinar 26apos 3BApplication of the ReactIR Flow Cell to Continuous Processing Tec 14728 3 COTR Refresher Course Offered 11 January 2010 28Wash DC Area 29 60727 1 COTR Refresher Course Offered 11 January 2010 28Wash DC Area 29 60727 2 COTR Refresher Course Offered 11 January 2010 28Wash DC Area 29 60727 3

[0] American Imaging Management's New Specialty Drug Program Delivers Immediate Results [0] AVAX Technologies, Inc. Closes Bridge Financing [0] Boston Scientific Announces Election of Nelda Connors to Its Board of Directors

... Aug. 21 ,Bayer HealthCare Pharmaceuticals, Inc. and ... announced the companies have begun enrolling patients,in ... the Prevention of,Recurrence of Hepatocellular Carcinoma trial. ... evaluating Nexavar(R) (sorafenib),tablets as adjuvant treatment, which ...

... Aug. 20 Enobia Pharma, an emerging biotech,company ... today announced that the first patient in its ... investigating Enzyme,Replacement Therapy (ERT) with ENB-0040 for the ... disorder for which there is no approved,treatment., ...

Other Medicine Technology:Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 2 Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 3 Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 4 Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 5 Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 2 Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 3

Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia

(Date:12/16/2009)... -- For wounded U.S. servicemen and women ... D.C., the holidays can be a particularly difficult time. ... rely more than ever on the healing power of ... home just got easier for Walter Reed patients as ... will provide hundreds of minutes of holiday talk time ...

(Date:12/16/2009)... possibly deadly, attack is long-term goal, researchers say ... developed a tool to predict whether a patient will ... first stroke. , "This is an important new tool ... second stroke soon after a first stroke are more ... Ay, of Massachusetts General Hospital and Harvard Medical School, ...

(Date:12/16/2009)... that could help ease health and environmental concerns about ... technology for changing the behavior of nanoparticles in municipal ... environment. Their study was published in ACS, journal ... the UK Centre for Ecology and Hydrology and colleagues ... of nanoparticles particles less than 1/1000th the width ...

(Date:12/16/2009)... Cost-Effective Care , ... Washington, D.C. (Vocus) December 16, ... ways to rein in runaway costs while providing care to all ... the ongoing discussion includes how to ensure patients equal access to ... (MDs) or osteopathy (DOs). In both the House and Senate ...

(Date:12/16/2009)... Specific Neurological Stress Reduction Therapy or NSRTSM is found very ... conditions such as allergies, asthma, migraines, chronic fatigue and a ... throughout the country are using this holistic therapy including over ... ... Minneapolis, MN (Vocus) December 14, 2009 -- ...

Breaking Medicine News(10 mins):Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2 Health News:New Stroke Tool May Predict Early Recurrence 2 Health News:Behavior modification could ease concerns about nanoparticles 2 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5

[0] Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital [0] New Stroke Tool May Predict Early Recurrence [0] Behavior modification could ease concerns about nanoparticles [1] Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs [0] BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening

... MILLS, Md., Oct. 30 Medifast, Inc.,(NYSE: MED ) ... 2008 financial results for the period ended September 30, 2008 ... call and web,cast to discuss the results on Thursday, November ... the call by dialing (866) 524-3160 or,(412) 317-6760, or can ...

... as One of the Top 10 Most Interesting ... Oct. 30 Genaera,Corporation (NASDAQ: GENR ) ... being held November 3-5 at the Lowes Hotel ... and,Chief Scientific Officer, will provide an overview on ...

... Cardo Medical, a company engaged,in the development ... of its Align 360 Total Knee System. The ... release during the second quarter of 2009.,Cardo Medical,s ... within,its Align 360 platform which has already received ...

... 2009 Operating Preview, MELVILLE, N.Y., Oct. 30 ... a leading provider of comprehensive home,health services, today ... and 26% operating contribution growth from its Home ... clinical innovation, quality and,productivity to enhance its industry ...

... by SEIU,Secretary-Treasurer Anna Burger on Barack Obama,s prime-time special:, ... voters will head to the polls,to choose a president ... biggest economic crisis since the Great Depression., "Tonight, ... right now--tax cuts for the middle class, affordable,healthcare for ...

... and mobile devices with wireless connectivity. , ... ... a provider of clinical information for healthcare professionals, is pleased ... that delivers Lexi-Comp,s drug, disease, and formulary content on smartphones ...

Medifast, Inc. to Announce Third Quarter of Fiscal Year 2008 Financial Results on Thursday, November 6, 2008 Genaera to Present at Therapeutic Area Partnerships 2008 Cardo Medical Announces FDA Clearance of the Align 360 Total Knee System Gentiva Reports Third Quarter Revenue and Profit Growth Obama Puts Healthcare, Economic Relief for Middle Class First in Prime-Time Special Lexi-Comp Point-of-Care Information Now Available on Smartphones, Coming Soon for the iPhone™

... Exp Expandable Tip System A ... System allows you to perform multi-sample transfers between ... pull of a knob, tip spacing can be ... microcentrifuge tubes) or 96 well plates. Ergonomic ...

... Exp Expandable Tip System A lower ... allows you to perform multi-sample transfers between two ... of a knob, tip spacing can be quickly ... tubes) or 96 well plates. Ergonomic Design ...

Medicine Products:

Impact2 EXP 8-Channel Electronic Pipettor, 15-1250L Impact2 EXP 8-Channel Electronic Pipettor, 2-125L Impact EXP 8-Channel Electronic Pipettor, 15-1250L Impact2 EXP 6-Channel Electronic Pipettor, 15-1250L

( ischaemic stroke significantly improve...)Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke,Health